索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]黄鲲,陈一泓,梁春.胎盘生长因子在动脉粥样硬化性心血管疾病 中的研究进展[J].国际心血管病杂志,2024,03:153-155,163.
点击复制

胎盘生长因子在动脉粥样硬化性心血管疾病 中的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年03期
页码:
153-155,163
栏目:
综述
出版日期:
2024-05-20

文章信息/Info

Title:
-
作者:
黄鲲; 陈一泓; 梁春
200433 上海，中国人民解放军海军军医大学（黄鲲）； 200003 海军军医大学第二附属医院（上海长征医院）（陈一泓， 梁春）
Author(s):
-
关键词:
胎盘生长因子; 动脉粥样硬化; 斑块
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.03.007
文献标识码:
-
摘要:
胎盘生长因子（PLGF）是血管内皮生长因子家族的重要成员，近年来发现其在 心血管疾病中发挥重要作用，有望作为动脉粥样硬化性心血管疾病（ASCVD）的干预靶标， 然而PLGF在ASCVD中的作用仍存在争议。该文介绍PLGF在ASCVD中的作用及研究进展。
Abstract:
-

参考文献/References

[1] Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor[J]. Proc Natl Acad Sci U S A, 1991, 88(20):9267-9271.
[2] Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, et al. Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: current research and future perspectives[J]. Cytokine Growth Factor Rev, 2018, 39:102-115.
[3] Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A[J]. Nat Rev Mol Cell Biol, 2023, 24(11):816-834.
[4] Zhu LY, Qian JQ, Jiang YN, et al. PlGF reduction compromises angiogenesis in diabetic foot disease through macrophages[J]. Front Immunol, 2021, 12:736153.
[5] Bj?rkegren JLM, Lusis AJ. Atherosclerosis: recent developments[J]. Cell, 2022, 185(10):1630-1645.
[6] Roncal C, Buysschaert I, Gerdes N, et al. Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions[J]. Cardiovasc Res, 2010, 86(1):29-36.
[7] Skoda M, Stangret A, Szukiewicz D. Fractalkine and placental growth factor: a duet of inflammation and angiogenesis in cardiovascular disorders[J]. Cytokine Growth Factor Rev, 2018, 39:116-123.
[8] Yang W, Ahn H, Hinrichs M, et al. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells[J]. J Reprod Immunol, 2003, 60(1):53-60.
[9] Iyer S, Leonidas DD, Swaminathan GJ, et al. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution[J]. J Biol Chem, 2001, 276(15):12153-12161.
[10] Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR[J]. Biochem Biophys Res Commun, 1996, 226(2):324-328.
[11] Draker N, Torry DS, Torry RJ. Placenta growth factor and sFlt-1 as biomarkers in ischemic heart disease and heart failure: a review[J]. Biomark Med, 2019, 13(9):785-799.
[12] Hayes Ryan D, McCarthy FP, O'Donoghue K, et al. Placental growth factor: a review of literature and future applications[J]. Pregnancy Hypertens, 2018, 14:260-264.
[13] Matsui M, Onoue KJ, Saito Y. sFlt-1 in chronic kidney disease: friend or foe?[J]. Int J Mol Sci, 2022, 23(22):14187.
[14] Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1[J]. Nat Med, 2003, 9(7):936-943.
[15] Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR[J]. J Biol Chem, 1996, 271(6):3154-3162.
[16] Apicella I, Cicatiello V, Acampora D, et al. Full functional knockout of placental growth factor by knockin with an inactive variant able to heterodimerize with VEGF-A[J]. Cell Rep, 2018, 23(12):3635-3646.
[17] Van Bergen T, Etienne I, Cunningham F, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases[J]. Prog Retin Eye Res, 2019, 69:116-136.
[18] Green CJ, Lichtlen P, Huynh NT, et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1[J]. Cancer Res, 2001, 61(6):2696-2703.
[19] Larcher F, Franco M, Bolontrade M, et al. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis[J]. Mol Carcinog, 2003, 37(2):83-90.
[20] Sissaoui S, Egginton S, Ting L, et al. Hyperglycaemia upregulates placental growth factor (PlGF) expression and secretion in endothelial cells via suppression of PI3 kinase-Akt signalling and activation of FOXO1[J]. Sci Rep, 2021, 11(1):16344.
[21] Hollborn M, Tenckhoff S, Seifert M, et al. Human retinal epithelium produces and responds to placenta growth factor[J]. Graefes Arch Clin Exp Ophthalmol, 2006, 244(6):732-741.
[22] Santalahti K, Havulinna A, Maksimow M, et al. Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study[J]. J Intern Med, 2017, 282(4):340-352.
[23] Borodulin K, Vartiainen E, Peltonen M, et al. Forty-year trends in cardiovascular risk factors in Finland[J]. Eur J Public Health, 2015, 25(3):539-546.
[24] Bui AH, Bonaca MP, Sabatine MS, et al. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial[J]. J Thromb Thrombolysis, 2012, 34(2):222-228.
[25] Matsui M, Samejima KI, Takeda Y, et al. Prognostic impact of placental growth factor on mortality and cardiovascular events in dialysis patients[J]. Am J Nephrol, 2015, 42(2):117-125.
[26] Matsumoto T, Uemura S, Takeda Y, et al. An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease[J]. Intern Med, 2013, 52(10):1019-1027.
[27] Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation[J]. Circulation, 2005, 111(21):2828-2836.
[28] McGraw AP, Bagley J, Chen WS, et al. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism[J]. J Am Heart Assoc, 2013, 2(1):e000018.
[29] Fahed AC, Jang IK. Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions[J]. Nat Rev Cardiol, 2021, 18(10):724-734.
[30] Lind L, Gigante B, Borné Y, et al. Plasma protein profile of carotid artery atherosclerosis and atherosclerotic outcomes: metaanalyses and mendelian randomization analyses[J]. Arterioscler Thromb Vasc Biol, 2021, 41(5):1777-1788.
[31] Folkersen L, Gustafsson S, Wang Q, et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals[J]. Nat Metab, 2020, 2(10):1135-1148.
[32] Zuo B, Zhu S, Zhong GT, et al. Causal association between placental growth factor and coronary heart disease: a Mendelian randomization study[J]. Aging (Albany NY), 2023, 15(19):10117-10132.
[33] Wu M, Pokreisz P, Swinnen M, et al. Sustained placental growth factor-2 treatment does not aggravate advanced atherosclerosis in ischemic cardiomyopathy[J]. J Cardiovasc Transl Res, 2017, 10(4):348-358.
[34] Zhang J, Shi J, Ma H, et al. The placental growth factor attenuates intimal hyperplasia in vein grafts by improving endothelial dysfunction[J]. Eur J Pharmacol, 2020, 868:172856.
[35] Chen YH, Nilsson AH, Goncalves I, et al. Evidence for a protective role of placental growth factor in cardiovascular disease[J]. Sci Transl Med, 2020, 12(572):eabc8587.
[36] Vergallo R, Crea F. Atherosclerotic plaque disruption and healing[J]. Eur Heart J, 2020, 41(42):4079-4080.
[37] Vergallo R, Crea F. Atherosclerotic plaque healing[J]. N Engl J Med, 2020, 383(9):846-857.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金青年科学基金项目（82100479）；国 家自然科学基金国际（地区）合作与交流项目（82120108004）
通信作者：梁春， E-mail：chunliang@smmu.edu.cn
更新日期/Last Update: 2024-05-20